Asset Details
Do you wish to reserve the book?
Effective drug combinations in breast, colon and pancreatic cancer cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effective drug combinations in breast, colon and pancreatic cancer cells
Do you wish to request the book?
Effective drug combinations in breast, colon and pancreatic cancer cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effective drug combinations in breast, colon and pancreatic cancer cells
2022
Overview
Combinations of anti-cancer drugs can overcome resistance and provide new treatments
1
,
2
. The number of possible drug combinations vastly exceeds what could be tested clinically. Efforts to systematically identify active combinations and the tissues and molecular contexts in which they are most effective could accelerate the development of combination treatments. Here we evaluate the potency and efficacy of 2,025 clinically relevant two-drug combinations, generating a dataset encompassing 125 molecularly characterized breast, colorectal and pancreatic cancer cell lines. We show that synergy between drugs is rare and highly context-dependent, and that combinations of targeted agents are most likely to be synergistic. We incorporate multi-omic molecular features to identify combination biomarkers and specify synergistic drug combinations and their active contexts, including in basal-like breast cancer, and microsatellite-stable or
KRAS
-mutant colon cancer. Our results show that irinotecan and CHEK1 inhibition have synergistic effects in microsatellite-stable or
KRAS
–
TP53
double-mutant colon cancer cells, leading to apoptosis and suppression of tumour xenograft growth. This study identifies clinically relevant effective drug combinations in distinct molecular subpopulations and is a resource to guide rational efforts to develop combinatorial drug treatments.
A survey of potency and efficacy of 2,025 clinically relevant two-drug combinations against 125 molecularly characterized breast, colorectal and pancreatic cancer cell lines identifies rare synergistic effects of anticancer drugs, informing rational combination treatments for specific cancer subtypes.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 13/109
/ 64/60
/ 96/1
/ 96/2
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - pharmacology
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Colon
/ Colonic Neoplasms - drug therapy
/ Colonic Neoplasms - genetics
/ Datasets
/ Drugs
/ Humanities and Social Sciences
/ Humans
/ Kinases
/ Mutants
/ Pancreatic Neoplasms - drug therapy
/ Pancreatic Neoplasms - genetics
/ Proto-Oncogene Proteins p21(ras) - genetics
/ Science
/ Tumors
